<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00579995</url>
  </required_header>
  <id_info>
    <org_study_id>120-05-FB</org_study_id>
    <nct_id>NCT00579995</nct_id>
  </id_info>
  <brief_title>A Prospective, Randomized TrialComparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate</brief_title>
  <acronym>PROTECt</acronym>
  <official_title>A Prospective, Randomized Trial Comparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate for the Prevention of Contrast-Induced Nephropathy in High-Risk Patients Undergoing Cardiac Catheterization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of oral N-acetylcysteine and intravenous
      sodium bicarbonate for the prevention of CIN after cardiac catheterization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is thought that N-acetylcysteine may reduce the ability of generated oxygen free radicals
      to damage cells by scavenging them. N-acetylcysteine may also increase the biologic effects
      of nitric oxide by combining with nitric oxide to form S-nitrosothiol, a more stable form and
      potent vasodilator. It also increases the expression of nitric oxide synthesis and may
      improve blood flow. Oxidants activate a signal-transduction cascade and molecular response
      that may initiate the cell-death pathway. These pathways seem to be sensitive to the redox
      state of the cell and are inhibited by N-acetylcysteine, which promotes pathways that lead to
      repair and survival whenever cells are under oxidant stress.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2005</start_date>
  <completion_date type="Anticipated">January 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to compare the effectiveness of two medications, oral N-acetylcysteine (mucomyst) and intravenous sodium bicarbonate, used to protect the kidneys from contrast injury during a cardiac catheterization</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Preserving Kidney Function in People Who Are at High Risk of Developing Contrast-induced Nephropathy</condition>
  <arm_group>
    <arm_group_label>1, oral N-Acetylcysteine</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2, Intravenous Sodium Bicarbonate</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral N-Acetylcysteine</intervention_name>
    <description>600 mg</description>
    <arm_group_label>1, oral N-Acetylcysteine</arm_group_label>
    <other_name>NAC</other_name>
    <other_name>N-Acetyl-L-Cysteine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Sodium Bicarbonate</intervention_name>
    <description>3mL/kg/hr for one hour pre-procedure and infused at 1mL/kg/hr for 6 hours post-procedure</description>
    <arm_group_label>2, Intravenous Sodium Bicarbonate</arm_group_label>
    <other_name>Sodium hydrogen carbonate</other_name>
    <other_name>sodium acid carbonate</other_name>
    <other_name>baking soda</other_name>
    <other_name>bicarbonate of soda CAS No.: 144-55-8</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: 19 years of age

          -  Baseline serum creatinine or

          -  Calculated creatinine

          -  Stable Renal Function

          -  Left Ventricular ejection fraction

          -  Non-pregnant, non-lactating females (all women of childbearing potential must have a
             negative serum pregnancy test. No contraception will be required

          -  Able to sign informed consent

        Exclusion Criteria:

          -  Acute renal failure

          -  History of Kidney transplant

          -  Currently receiving N-acetylcysteine

             _ Contraindication of hypersensitivity to N-acetylcysteine or sodium bicarbonate

          -  Left ventricular ejection fraction

          -  Pregnant, lactating females

          -  Allergy to contrast dye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Shurmur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-2265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Shurmur, MD</last_name>
      <phone>402-559-5151</phone>
      <email>sshurmur@unmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Andre P Bouhasin, MD</last_name>
      <phone>402-559-5151</phone>
      <email>abouhasi@unmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Scott Shurmur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2007</study_first_posted>
  <last_update_submitted>June 25, 2010</last_update_submitted>
  <last_update_submitted_qc>June 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Scott Shurmur, M.D.</name_title>
    <organization>University of Nebraska Medical Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 20, 2012</submitted>
    <returned>July 24, 2012</returned>
    <submitted>December 16, 2013</submitted>
    <returned>February 4, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

